Michelle Lightfoot

Dr. Michelle Lightfoot

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2019 in Cancer Research
Verified
Journal Article
Closed access
PDF file
KDKalpana Deepa Priya Dorayappan
Kalpana Deepa Priya Dorayappan
MGMiranda Gardner
Miranda Gardner
CHColin Lee Hisey
Colin Lee Hisey
RZRoman A. Zingarelli
Roman A. Zingarelli
BSBrentley Q. Smith
Brentley Q. Smith
KSKaruppaiyah Selvendiran
Karuppaiyah Selvendiran
Because of limits on specificity and purity to allow for in-depth protein profiling, a standardized method for exosome isolation has yet to be established. In this study, we describe a novel, in-house microfluidic-based device to isolate exosomes from culture media and patient samples. This technology overcomes contamination issues because sample separation is based on the expression of highly specific surface markers CD63 and EpCAM. Mass spectrometry revealed over 25 exosome proteins that are differentially expressed in high-grade serous ovarian cancer (HGSOC) cell lines compared with normal cells—ovarian surface epithelia cells and fallopian tube secretory epithelial cells (FTSEC). Top exosome proteins were identified on the basis of their fold change and statistical significance between groups. Ingenuity pathway analysis identified STAT3 and HGF as top regulator proteins. We further validated exosome proteins of interest (pSTAT3, HGF, and IL6) in HGSOC samples of origin-based cell lines (OVCAR-8, FTSEC) and in early-stage HGSOC patient serum exosome samples using LC/MS-MS and proximity extension assay. Our microfluidic device will allow us to make new discoveries for exosome-based biomarkers for the early detection of HGSOC and will contribute to the development of new targeted therapies based on signaling pathways that are unique to HGSOC, both of which could improve the outcome for women with HGSOC. Significance: A unique platform utilizing a microfluidic device enables the discovery of new exosome-based biomarkers in ovarian cancer.

1 February 2017 in Journal of Minimally Invasive Gynecology
Verified
Journal Article
Closed access
RARoa Alammari
Roa Alammari
MLMichelle Lightfoot
Michelle Lightfoot
HHHye-Chun Hur
Hye-Chun Hur

1 December 2019 in OncoTargets and Therapy
Verified
Journal Article
Open access
PDF file
LMLauren Montemorano
Lauren Montemorano
MLMichelle Lightfoot
Michelle Lightfoot
KBKristin Bixel
Kristin Bixel
PARP inhibitors have shown significant promise in the treatment of ovarian cancer. Olaparib is a PARP inhibitor that has been approved for maintenance for BRCA-mutated ovarian cancer in the recurrent and front-line setting as well as for treatment of BRCA-mutated ovarian cancer in patients who have received multiple prior lines of chemotherapy. In this review, we focus on the use of olaparib in the maintenance setting including the evidence to date, ongoing research, and future directions.

24 September 2023 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Closed access
SLSarah Lee
Sarah Lee
ADAndreea I. Dinicu
Andreea I. Dinicu
LALikolani Arthurs
Likolani Arthurs
DSDanielle Shields
Danielle Shields
BPBhavana Pothuri
Bhavana Pothuri
MLMichelle Lightfoot
Michelle Lightfoot

1 July 2025 in International Journal of Gynecological Cancer
Verified
Journal Article
Closed access
MLMichelle Lightfoot
Michelle Lightfoot
MRMaria M. Rubinstein
Maria M. Rubinstein
BMBradley J. Monk
Bradley J. Monk
RERamez N. Eskander
Ramez N. Eskander
KLKathleen Lutz
Kathleen Lutz
BPBhavana Pothuri
Bhavana Pothuri

1 March 2022 in Gynecologic Oncology
Verified
Journal Article
Closed access
MLMichelle Lightfoot
Michelle Lightfoot
AFAshley S. Felix
Ashley S. Felix
EBErin E. Bishop
Erin E. Bishop
AHAlexa P. Henderson
Alexa P. Henderson
MVMonica H. Vetter
Monica H. Vetter
FBFloor J. Backes
Floor J. Backes